Although the mechanism of gilteritinib-induced endocrine grand disruption remains elusive, in our patient, FLT3 inhibitors caused secondary hypoadrenocorticism and central hypothyroidism, and over time after discontinuation, symptoms improved and hormone levels recovered. This evidence concerns the gene FLT3 and Central hypothyroidism.